Abstract
Aging, HIV infection, and antiretroviral therapy have been associated with increasing rates of chronic comorbidities in patients with HIV. Urban minority populations in particular are affected by both the HIV/AIDS and chronic disease epidemics. Our objectives were to estimate the prevalence of and risk factors for hypertension, dyslipidemia, and diabetes among HIV-infected adults in the Bronx and describe comorbidity-related treatment outcomes. This was a cross-sectional study of 854 HIV-positive adults receiving care at 11 clinics which provide HIV primary care services; clinics were affiliated with a large urban academic medical center. Data on blood pressure (BP), cholesterol, and glycemic control were collected through standardized chart review of outpatient medical records. We found prevalence rates of 26%, 48%, and 13% for hypertension, dyslipidemia, and diabetes, respectively. Older age, obesity, family history, and current protease inhibitor use were consistently associated with comorbidity. Diabetes treatment goals were achieved less often than BP and lipid goals, and concurrent diabetes was a significant predictor for BP and lipid control. In conclusion, major cardiovascular-related comorbidities are prevalent among HIV-positive adults in the Bronx, especially older and obese individuals. Differences exist in comorbidity-related treatment outcomes, especially for patients with concurrent diabetes. Because cardiovascular risk is modifiable, effective treatment of related comorbidities may improve morbidity and mortality in HIV-infected patients.
Similar content being viewed by others
References
Justman JE, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003; 32(3): 298–302.
Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005; 165(10): 1179–84.
Glass TR, Ungsedhapand C, Wolbers M, et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV cohort study. HIV Med. 2006; 7(6): 404–10.
Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006; 43(1): 27–34.
Adeyemi O, Vibhakar S, Max B. Are we meeting the American Diabetes Association goals for HIV-infected patients with diabetes mellitus? Clin Infect Dis. 2009; 49(5): 799–802.
Bury JE, Stroup JS, Stephens JR, Baker DL. Achieving American Diabetes Association goals in HIV-seropositive patients with diabetes mellitus. Proc Bayl Univ Med Cent. 2007; 20(2): 118–23.
Centers for Disease Control and Prevention. HIV prevalence estimates—United States, 2006. MMWR. 2008; 57(39): 1073–6.
Link CL, McKinlay JB. Disparities in the prevalence of diabetes: is it race/ethnicity or socioeconomic status? Results from the Boston Area Community Health (BACH) survey. Ethn Dis. 2009; 19(3): 288–92.
Clark AM, DesMeules M, Luo W, Duncan AS, Wielgosz A. Socioeconomic status and cardiovascular disease: risks and implications for care. Nat Rev Cardiol. 2009; 6(11): 712–22.
Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine association of the infectious diseases society of America. Clin Infect Dis. 2009; 49(5): 651–81.
Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003; 289(19): 2560–72.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486–97.
American Diabetes Association. Standards of medical care in diabetes—2008. Diab Care. 2008; 31(Suppl 1): S12–54.
Jung O, Bickel M, Ditting T, et al. Hypertension in HIV-1-infected patients and its impact on renal and cardiovascular integrity. Nephrol Dial Transplant. 2004; 19(9): 2250–8.
Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active antiretroviral therapy (HAART) compared with HAART-naïve and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis. 2003; 22(12): 731–6.
Crum-Cianflone N, Tejidor R, Medina S, Barahona I, Ganesan A. Obesity among patients with HIV: the latest epidemic. AIDS Patient Care STDs. 2008; 22(12): 925–30.
Korthuis PT, Asch SM, Anaya HD, et al. Lipid screening in HIV-infected veterans. J Acquir Immune Defic Syndr. 2004; 35(3): 253–60.
Bell TJ, Tang S, Jamieson MJ. Evaluation of hypertension prevalence and blood pressure goal attainment using data from the 1999–2000 national health and nutrition examination survey (NHANES). Am J Hypertens. 2004; 17(5): S193.
Pearson TA, Laurora L, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemia patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000; 160(4): 459–67.
Beaton SJ, Nag SS, Gunter MJ, Gleeson JM, Sajjan SS, Alexander CM. Adequacy of glycemic, lipid, and blood pressure management for patients with diabetes in a managed care settings. Diab Care. 2004; 27(3): 694–8.
Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004; 291(3): 335–42.
Justice AC. Prioritizing primary care in HIV: comorbidity, toxicity, and demography. Top HIV Med. 2006; 14(5): 159–63.
Acknowledgments
The authors gratefully acknowledge the support and helpful contributions of the Research Division in the Department of Family and Social Medicine at Montefiore Medical Center, the Albert Einstein College of Medicine’s Clinical Research Training Program, and the MMG/Bronx Community Health Network’s CICERO program.
Financial Support
This work was funded through the New York State Department of Health’s Empire Clinical Research Investigator Program. In addition, it was made possible by CTSA Grants UL1 RR025750, KL2 RR025749, and TL1 RR025748 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessary represent the official view of the NCRR or NIH.
Author information
Authors and Affiliations
Corresponding author
Additional information
Previous presentations
A portion of the data was presented in poster format at the 2009 AHRQ Practice-Based Research Network Conference in Bethesda, Maryland (June 24–26, 2009) and at the 2010 International AIDS Conference in Vienna, Austria (July 18–23, 2010).
Rights and permissions
About this article
Cite this article
Chu, C., Umanski, G., Blank, A. et al. Comorbidity-Related Treatment Outcomes among HIV-Infected Adults in the Bronx, NY. J Urban Health 88, 507–516 (2011). https://doi.org/10.1007/s11524-010-9540-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11524-010-9540-7